Table 13.6a

Immunosuppression Use for Induction, 1997 to 2006

Recipients with Heart-Lung Transplants

  Year of Transplant
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Transplants 62 47 51 48 27 33 29 40 35 31
With Immunosuppression Info 58 45 50 48 26 33 28 38 33 30
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 25.9% 20.0% 16.0% 29.2% 26.9% 15.2% 3.6% 13.2% 12.1% 3.3%
OKT3 6.9% 6.7% 10.0% 6.3% 0.0% 6.1% 3.6% 2.6% 3.0% 0.0%
Thymoglobulin 0.0% 0.0% 4.0% 4.2% 11.5% 3.0% 10.7% 13.2% 3.0% 6.7%
Zenapax 0.0% 0.0% 4.0% 12.5% 7.7% 15.2% 7.1% 18.4% 12.1% 16.7%
Simulect 0.0% 0.0% 0.0% 4.2% 30.8% 18.2% 17.9% 10.5% 24.2% 10.0%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 5.3% 9.1% 23.3%
No Induction Drugs Recorded 70.7% 75.6% 66.0% 47.9% 26.9% 42.4% 57.1% 42.1% 39.4% 40.0%


Source: OPTN/SRTR Data as of May 1, 2007.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.